Clinical Trial Update: Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase neoadjuvant study evaluating the immunogenicity and biomarker signals of ipilimumab in melanoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma | EARLY_Phase 1 | Status: COMPLETED